Statins: Apocalypse or Pleiotropic Nirvana? Why Statins Will Not End Civilization, Nor Cure All Ills

Feb 18

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making decisions about your medical care. CardioAdvocate does not provide medical advice, and information presented here should not be used to diagnose, treat, cure, or prevent any disease or condition.

Case Presentation

A 65-year-old male with previous 2-vessel coronary artery bypass surgery at age 50 and severely elevated LDL-C at 219 mg/dL (see: The Repeat Offender (The Heart Attack Survivor)) with a strong family history of premature coronary artery disease (brother died of a heart attack in his mid-40s and his father had his first heart attack in his 50s and died of another in his 70s) is referred to the cardiology clinic.

He declines statin therapy due to beliefs in the "inflammation theory of atherosclerosis" through his own readings and research. He further explains that since he works in the nutraceutical industry, he fears his boss would look down upon him if he found out he was taking a statin.

After much counseling, he agrees to try a statin. At the follow-up visit 2 months later, however, he admits he never started it; favoring diet and lifestyle measures which he proudly reports dropped his LDL-C by 30 points to 189 mg/dL. The cardiologist congratulates him on the positive change, but informs him that it isn't enough to significantly alter the course of the disease. He again agrees to reconsider the statin.

His cardiologist submits genetic testing through Ambry Genetics, which confirms suspicion for heterozygous familial hypercholesterolemia (see: Hiding in Plain Sight - Familial Hypercholesterolemia) and the statin myopathy gene. He cancels his follow-up visit and this time returns 6 months later and reports that he failed the statin due to fatigue and myalgias. He is prescribed evolocumab (Repatha), a PCSK9 monoclonal antibody inhibitor.

It's the beginning of the year and with insurance coverage changes, another 6 weeks goes by and the expensive branded drug is finally approved. By this time, he is enjoying a much anticipated extended vacation in Hawaii and sends a message asking for the prescription to be sent to a local pharmacy.

Four weeks later he suffers sudden cardiac arrest while surfing. After 75 minutes of CPR by surrounding surfers, weeks in the ICU, intubated, on continuous dialysis, with discussions of withdrawing care, he makes a miraculous full recovery and returns to see his cardiologist in clinic.

Flying Under the Radar

This case above illustrates several layers of complexity, making this phenotype a particularly dangerous, underappreciated, undertreated and forgotten patient.

It's not as simple as "take your medicine." Or, "trust us, we're doctors." These issues are nuanced and require individualized discussion and education on both sides of the patient-clinician relationship. For more information about statin challenges and alternatives, see There's an App for That — Risk Calculators and our comprehensive article on statin options.

With cult-like fervor, statins have become one of the more polarizing topics in all of medicine. On the one extreme, there are those who believe statins represent all that is evil in medicine and are responsible for every major ailment to include diabetes, Alzheimer's and coronary calcification. On the other extreme, there are those advocating that we put statins in the water. Both extremes are ridiculous.

Statins are highly effective, safe, inexpensive and widely available medications. However, they may not be enough and their clinical value needs to be put in perspective. Statins, apart from the LDL-C lowering effects (which itself represents an historical medical revolution not seen since the discovery of penicillin and the polio vaccine), don't necessarily offer additional "magical" qualities.

There was a time in medicine (in the mid-2000s), primarily driven by cardiologists, where there was an intense belief in the pleiotropic effects of statins. These were so-called "anti-inflammatory" effects that were unrelated to LDL particle lowering. The enthusiasm was so great, it prompted the comment "among clinicians the pleiotropic benefits of statins have reached almost mythical proportions" in an editorial in 2005 (Clinical Significance of Statin Pleiotropic Effects | Circulation), by Michael H. Davidson, MD - UChicago Medicine, renowned lipidologist. But alas, what's been borne out from subsequent clinical trials of other non-statins and in line with the Cholesterol Treatment Trialists Findings — CTT Collaboration, "it's the particles, stupid."

While there may be obstacles in treating this phenotype, failure is not an option. Not today. Not with the tools we currently have available.

Don't let statin intolerance prevent you from tackling and overcoming atherosclerotic disease. We have more than one tool now for eradicating heart disease.

CardioAdvocate Checklist

Patient & Clinician Assessment

Initial Steps:

Visit the ACC Statin Intolerance App - American College of Cardiology to further assess for typical characteristics of statin intolerance and expert guidance and management

Consider More Common Alternative Causes for Myopathy:

DOMS (Delayed Onset Muscle Soreness) following a workout
Degenerative Joint Disease
Degenerative Arthritis
Hypothyroidism
Vitamin D deficiency

Treatment Optimization Strategies:

Reduce dose of current statin to ¼ of previous dose
Switch to another statin
Try a combination approach with lower dose of statin with ezetimibe
Hack: Ezetimibe typically reduces LDL-C only 10-15% when used as sole therapy, but when coupled with any statin, will produce 20-25% reduction in LDL-C. So, ezetimibe when used with any modest intensity statin or dosing is equivalent to high intensity statin (> 50% LDL-C reduction)
Consult with a lipid specialist: Find a Clinician: LearnYourLipids

Deep Dive

Undertreated

Patients with statin intolerance are invariably undertreated for their cardiometabolic risk. There are a number of reasons for this. As illustrated above, there are inevitable delays in achieving adequate treatment. The higher their baseline risk, the more aggressive the treatment needs to be to achieve the more rigorous therapeutic targets for optimal management. Coupled with typical delays in healthcare access, unforeseeable appointment cancellations, the need for repeat laboratory testing and insurance prior authorizations to include the requirements to try and fail multiple statin regimens and combinations (not an unreasonable request, but a delay nonetheless) it's not hard to fathom months, if not years going by before a patient finally achieves therapeutic goals. The majority never do. And that's AFTER the clinician gets buy-in from the patient.

How Common is Statin Intolerance?

In randomized clinical trials (RCT), 1:1000 blinded patients stop their statin due to adverse effects, mostly myalgias. In clinical practice (prevention clinic), about 15% of patients report adverse effects. The truth lies somewhere in between. There are biases present everywhere. This topic is no different. RCT participants suffer from a participation bias. They tend to tolerate things.

Clinical trials using patients as their own control (double crossover), demonstrate that the vast majority (90%) of cases of statin intolerance are attributable to the nocebo effect, meaning that they attribute an unfavorable side effect to a placebo. But that leaves 10% experiencing true myalgias. In the case above, the patient tested positive for the simvastatin statin myopathy gene, which may increase the likelihood of true statin myopathy and intolerance. It is well documented that patients with FH tend to have a higher rate of statin myopathy. They also tend to have a blunted response to statins (or any LDL lowering therapy which works by upregulating LDLR).

The Forgotten Patient

When patients become labeled as "statin intolerant," they often fail to achieve optimal lipid levels despite the availability of alternative techniques and highly effective and safe non-statin therapies. The reasons for this are multifactorial. Clinicians often lack the tools to distinguish true statin intolerance from other more common complaints. Even with such tools, they often lack the time (and sometimes interest) to spend with patients on this particular issue. Patients on the other hand, are exposed to a plethora of misinformation - whether it's from Aunt Sally, their neighbor Joe or the growing number of "self-proclaimed" non-medical experts promoting misinformation on social media to enhance their followership (See: The Straw That Breaks the Camel's Back - LMHR (Lean Mass Hyper Responder)). This, coupled with the growing struggles with access to specialists leads suboptimal treatment of an already identified high-risk population of patients.

This is particularly frustrating when, as described elsewhere, we've already cleared two big hurdles in 1) Identifying a high-risk patient and 2) getting that patient access to a clinician capable of treating such cardiometabolic risk, only to be tripped up by a poorly understood but exaggerated entity, sending patients running away from the therapy that may save their lives.

Whether its frustration, apathy or the lack of access or time this aspect of cardiometabolic risk becomes listed in the chart as "statin intolerance" as if to say "well, we tried and it didn't work, so stop addressing it" and the patient is left behind. This unfortunately becomes a major source of "residual risk."

Risk of Dementia

There has been no signal of dementia with regards to statins. Aggressive lowering of LDL-C has not demonstrated any increased risk for dementia, cognitive dysfunction or hemorrhagic stroke. See this Scientific statement from the American Heart Association: Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association (2023) | Arteriosclerosis, Thrombosis, and Vascular Biology

For additional discussion, see Forget Me? — Not! The Myth of Statins and Dementia (coming soon)

Risk of Liver Damage

The following statements can be obtained from: An assessment by the Statin Liver Safety Task Force: 2014 update - Journal of Clinical Lipidology

Statins are associated with elevated liver enzymes
Statin-associated elevations in liver enzymes are not indicative of liver damage or dysfunction
Statins do not increase the risk of liver failure
Routine liver enzyme checks are not recommended for monitoring patients taking statins
Statins are safe with nonalcoholic fatty liver disease (NAFLD)
Chronic liver diseases to include compensated cirrhosis are not contraindications for statins
Statins should be stopped when liver enzymes are greater than 3 times the upper limit of normal, to allow for appropriate diagnostic workup and rule out all potential causes
Statins do not need to be stopped if liver enzymes are less than 3 times the upper limit of normal and the bilirubin and creatine kinase are not elevated. The presence of NAFLD should be assessed, however

Risk of Diabetes

Multiple studies have demonstrated that statins have been associated with an increase in the rate of diabetes (Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial | BMJ 2023). The risk is higher at the higher dosing spectrum of a statin and seen more in those with dysglycemia already present, such as those with prediabetes, impaired glucose tolerance or metabolic syndrome. However, these patients are already at greater risk for ASCVD events and the net result is a greater overall benefit to statin therapy. It's important to recall that the #1 cause of demise in the diabetic (and prediabetic) population is ASCVD, driven by atherothrombotic (plaque rupture) physiology. Strict glycemic control in diabetics has not been shown to improve ASCVD (macrovascular) complications, but rather, they improve microvascular complications, which is also important. The more promising new diabetes medications such as SGLT2i and GLP-1 agonists improve CV risk independent of glycemic impact.

Statins Raise Lp(a)

While statins may raise Lp(a) 10-20%, LDL particles represent the majority of atherogenic particles. When fending off your castle against multiple armies, if you have the ability to obliterate the largest group of attackers, then the smaller group with the more impenetrable armor may have less of a chance to invade your walls.

Nonetheless, this increase in Lp(a) may explain residual risk in statin trials.

But until we have direct therapies against Lp(a), proven to reduce ASCVD risk, we need to continue to focus on the primary driver of this disease: LDL.

Statins Increase Coronary Artery Calcification (they don't cause coronary artery disease)

Is that a bad thing? Depends. It could be a good thing, if it represents plaque stabilization. But it's certainly plausible (perhaps more likely), that the prescribing clinician is not being nearly aggressive enough to get out in front of the disease (in high-risk patients, we are much more likely to undertreat this disease), to the extent that the calcium score continues to increase despite being placed on a statin regimen.

But let's be clear, an increase in CAC is not the same thing as causing coronary artery disease.

Remember, coronary artery calcification (CAC) is not the target of lipid lowering therapy. It's the lower density, soft, cheesy, toothpaste, or "abscess-like," crud that resides adjacent to the CAC that we are fighting. This is the stuff that is breaking down the architecture of the plaque and will eventually lead to fissuring or frank rupture of the plaque, spewing its nasty (and thrombogenic) contents into the lumen of the artery - like a zit on a teenager's face.

CAC represents the by-product of plaque inflammation. CAC Agatston scoring is derived from the calcification lesion area x density score (see: A Picture is Worth a Thousand Words - Coronary Artery Calcium Scores). When high-intensity statins (or any other potent lipid lowering therapy) are employed, we hope to promote plaque stabilization, which causes a regression in the soupy necrotic core of the plaque, increasing plaque density and therefore increasing subsequent CAC scores. In general, the CAC score should increase about 20-30% post statin treatment. Beyond that, one may question whether the disease is progressing despite our best efforts. This is a controversial topic - repeat CAC testing post-statin. Better technology is needed (and being developed: Cleerly), but these are the limitations of the present data and technology.

2026 Update: The CTT Landmark — What the Largest Safety Meta-Analysis Actually Shows

In February 2026, the Cholesterol Treatment Trialists' Collaboration published a landmark meta-analysis in the Lancet. This wasn't just another study—it was the study of studies. Experts like Kausik Ray called it "a really significant publication" that "refutes [prior skepticism] beyond reasonable doubt."

What did they find? Researchers analyzed 19 double-blind randomized controlled trials involving nearly 124,000 participants followed for a median of 4.5 years. They tested every single one of the 66 undesirable effects listed on statin product labels to see which ones were actually caused by the drug.

The headline: Of those 66 listed side effects, statins actually caused just 4. We already knew about muscle symptoms and diabetes. The meta-analysis confirmed a few others—some liver enzyme abnormalities, urinary changes, and mild swelling. That's it.

But here's what matters most: Things you've been warned about—things that might have scared you away from statin therapy or made you stop taking it—simply aren't caused by statins. The study found no causal relationship between statins and cognitive impairment, depression, sleep disturbance, or peripheral neuropathy—all of which are currently listed on product labels. That means if you've stopped a statin because you were worried about these side effects, you may have stopped it unnecessarily.

The researchers put it plainly: "Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions listed in product labels as potential undesirable effects. Such labelling and other official sources of health information should be revised."

Questions to Ask Your Doctor

"I've heard statins cause cognitive problems, depression, or nerve damage. What does the actual trial evidence show?" The largest, most rigorous evidence base we have says statins don't cause these. That's worth knowing before you decide to avoid or stop therapy.
"The new Lancet meta-analysis of 124,000 patients found most listed side effects aren't actually caused by statins. Can we revisit whether a statin is right for me?" If you've been labeled "statin intolerant" based on vague or common symptoms, this new evidence might change the conversation. It's worth asking.
"I stopped my statin because of [symptom]. Is there evidence that symptom was actually caused by the statin?" This is the key question. The CTT meta-analysis gives you and your doctor data to answer it honestly. If the symptom isn't on the list of confirmed statin side effects, it may be worth reconsidering or trying a different approach.

The Bottom Line

This 2026 meta-analysis is exactly the kind of evidence-based science that should inform conversations between patients and clinicians. If fear of side effects has held you back from statin therapy, or if you've stopped taking one, this research deserves a place in your decision. Cardiovascular disease remains the leading cause of death in the developed world. Getting to your lipid targets matters—and the fear of phantom side effects shouldn't stand in your way.

CardioAdvocate helps people understand what matters — and how to speak up about it.

LDLcholesterolatherosclerosisside effectsAlzheimersliver enzymesdiabetes

Ian Riddock